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Abstract
Glioblastomas exploit various molecular pathways to promote glutamate- dependent growth by activating the AMPA (2-
amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid) receptor, the group II metabotropic glutamate receptor, mGluR,
and the epidermal growth factor receptor, EGFR. We hypothesized that targeting more than one of these pathways would
be more effective in inhibiting glutamate-dependent growth. Using a model of U87 cell line, we show that blocking
glutamate release by Riluzole inhibits cell proliferation. Glutamate-dependent growth is effectively inhibited by a
combination of Iressa, an inhibitor of EGFR activation and LY341495, a group II mGluR inhibitor. Treatment of U87 cells with
a combination of Iressa and LY341495 inhibits proliferation as indicated by Ki-67 staining, induces apoptosis and inhibits
migration of U87 cells more effectively than the treatment by Iressa or LY341495 alone. These results demonstrate that a
combinatorial therapy with Iressa and LY341495 is more effective due to synergistic effects of these drugs in inhibiting the
growth of glioblastoma.
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Introduction
Glioblastoma multiforme, one of several kinds of gliomas, is a
cancer of astrocytes in the brain and the spinal cord, and is the
most common and malignant form of cancer of the central
nervous system (CNS) [1]. Glioblastomas are high-grade (grade 4
gliomas) cancers, with a poor prognosis for patients due to their
aggressive growth behavior and highly invasive nature [2,3].
Treatment options for glioblastoma are limited to surgery,
chemotherapy, and radiation with a poor survival outcome.
Moreover, surgical intervention is often ineffective due to the
invasive nature of the tumor [4,5].
Many gliomas have been shown to release high levels of
glutamate, which promotes malignancy [6,7,8]. More specifically,
glutamate levels in U87 cells culture media were high due to its
secretion [9]. Glutamate activates both fast-acting ionotropic and
slow-acting metabotropic glutamate receptors in glial cells and is
an important key regulator of invasive growth of glioblastoma
[10]. Autocrine secretion of glutamate is up-regulated by cysteine-
glutamate exchange [8,11]. Additionally, low re-uptake of
glutamate by loss of excitatory amino acid transporter (EAAT2)
[7,8] contributes to excess glutamate. The presence of excessive
glutamate promotes invasive growth of glioblastoma cells and kills
surrounding neurons due to glutamate neurotoxicity [7,12].
Activation of ionotropic glutamate receptors, particularly that of
the AMPA receptors plays a crucial role in growth and migration
of glioblastoma cells [13]. AMPA receptors assemble as homo or
hetero tetramers of GluR1-4 subunits and depending on subunit
composition AMPA receptors form Ca2+-permeable (GluR1, 3, 4)
or Ca2+-impermeable (GluR2-containing) channels. GluR2-con-
taining AMPA receptors are Ca2+-impermeable due to the
presence of an arginine at the pore apex, which is introduced
post-transcriptionally by RNA editing [14,15]. In the CNS,
AMPA receptors in general are Ca2+-impermeable. However, in
high-grade gliomas AMPA receptors lack GluR2 subunit forming
Ca2+-permeable channels [16,17]. Furthermore, glioma cells
lacking GluR2 showed enhanced migration and, importantly,
blocking of Ca2+ influx via AMPA receptor antagonist, NBQX,
inhibited growth and induced apoptosis [13,18]. Unedited GluR2
was detected in primary human glioblastoma cell lines VU-028
and VU-122 but not in U87 cell line [19]. Unedited GluR2 in
neurons promotes excitotoxic death when exposed to high
glutamate levels via Ca2+ influx and enhanced trafficking of the
Ca2+- permeable AMPA receptors [20]. High levels of glutamate
also promote cleavage of editing enzyme ADAR2 that results in
lower GluR2 editing in neurons, which may lead to excitotoxic
death in neurons [21]. In contrast, over expression of Ca2+-
permeable AMPA receptors enhanced growth proliferation of
glioma cells in low serum conditions [22]. Although growth of U87
cell proliferation depends both on growth factors and activation of
AMPA receptor, the role of AMPA receptor in growth enhance-
ment is evident at low serum concentrations [22]. Thus high levels
of glutamate promote proliferation of glioma cells while killing
neurons due to excitotoxicity [20,21].
Ca2+ influx via AMPA receptors initiates Ca2+ signaling
cascades and promotes Ca2+-dependent growth via the activation
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of protein serine threonine kinase, Akt [17]. Akt signals protein
synthesis, which allows cell survival and growth, while inhibiting
apoptosis, and is crucial for conversion of anaplastic astrocytoma
to glioblastoma [23]. Akt activation occurs via phosphorylation of
two key residues, threonine 308 in the kinase domain and serine
473 in the C terminal regulatory domain. The phosphorylation of
these residues is tightly regulated. Activation of Ca2+permeable
AMPA receptor leads to Ca2+-dependent activation of Akt by its
phosphorylation at serine 473 by an unidentified kinase and at
threonine 308 by Ca2+-independent mechanism in CGNH-89
glioblastoma cell line [17]. Others have shown that threonine 308
phosphorylation is activated by PDK1 [24,25,26,27]. Full
activation of Akt requires phosphorylation at threonine 308 and
serine 473 and threonine activation is a crucial step for complete
activation of Akt [28,29].
Glutamate stimulates the up-regulation of epidermal growth
factor receptor (EGFR) in glioblastoma cell line, U87 [30]. In
40–50% of glioblastomas EGFR is present at levels several-fold
higher compared to the levels in normal cells [31,32].
Epidermal growth factor receptor stimulation causes the
activation of phosphatidylinositol-3-OH kinase (PI3 K), which
converts membrane phosphatidylinositiol (5,5)-bisphosphate
(PIP2) to phosphatidylinositol (3,4,5)-triphosphate (PIP3). PIP3
in the membrane recruits and activates Akt [33,34]. Iressa is an
EGFR inhibitor that blocks the activity of EGFR and stops cell
growth and has been shown to inhibit glioblastoma cell growth
[30]. Interestingly, heterodimeric EGFR receptors activate
P13 K pathway and may be activating growth in glioblastoma
via Akt activation [30,35,36,37]. A specific inhibitor, LY294002,
inhibits PI3 K and blocks phosphorylation of Akt [17].
Wortmannin inhibits phosphorylation of Akt on threonine 308
by inhibiting P13 K that activates PDK1 [29,38].
EGFR activation in gliomas also leads to activation of the MAP
kinase pathway [39]. MAP kinase pathways regulate proliferation,
differentiation and survival of cells in several types of tumors
including glioma [40]. ERK1 and 2 are members of the MAP
kinase pathway that are regulated by phosphorylation, and have
been targeted by drugs to reduce proliferation in glioma [41].
Glutamate stimulates growth of glioblastoma by activating the
metabotropic glutamate receptors, mGluR. Drugs such as
LY341495, that specifically block group II (mGluR2/3) mGluRs,
are reported to inhibit the growth of glioblastoma cells in vivo
[9,42]. Group II mGluR in U87 cells have been shown to activate
both P13 Kinase pathway and MAP kinase pathway. Further-
more, inhibition by LY341495 resulted in reduced activation of
both Akt phosphorylation as well as ERK1/2 phosphorylation in
U87 cells [9]. Signaling pathways stimulated by glutamate, site of
action of drugs used and convergence of the signaling pathways is
shown in Figure 1.
Thus, glutamate appears to stimulate multiple pathways to
modulate the invasive growth of glioblastoma (Figure 1). Drugs
that block the activation of these pathways, such as AMPA
receptor by antagonist, NBQX, mGluR2/3 inhibitor, LY341495,
EGFR inhibitor, Iressa, Akt activation inhibitors Wortmannin and
LY294002 have been shown to reduce the growth of glioblastoma
when used independently [9,13,17,30]. Besides the activation of
the glutamate receptors such as AMPA receptor, mGluR and
EGFR, Akt activation is involved in the stimulation of growth by
more than one pathway (AMPA receptor and EGFR receptor and
mGluR activation). Furthermore, the MAP kinase pathway is
activated via both EGFR and mGluR activation [9,41,42]. An
effective treatment may necessitate the use of more than one drug
for a more vehement inhibition of growth. We hypothesize, that a
particular/selective combination of these drugs will work more
effectively to inhibit the growth of U87, glioblastoma cells,
compared to the use of individual drugs. U87 cells have been
shown to secrete high levels of glutamate that aids invasive growth
[11]. We report in the present study that a combination of
LY341495, a selective blocker of mGluR2/3, and Iressa, an
EGFR blocker, work most efficiently to inhibit both proliferation
and migration of U87 cells and induced maximum apoptosis in the
U87 cells. Such a drug combination may be useful in combina-




U87 cells were maintained in DMEM supplemented with
2 mM glutamate, 4.5% glucose, 1 mM pyruvate, 10% fetal bovine
serum, 100 units/mL penicillin, and 100 mg/mL streptomycin.
Cells were passaged every 4 days. Cells were maintained at 37uC
with 95% air and 5% CO2. For experiments, cells were seeded in
MEM media without glutamate, penicillin, and streptomycin, and
0.5% fetal bovine serum.
Drug Treatments
2.56104 cells were seeded onto polylysine coated coverslips in a
24 well plate. Twenty-four hours later the cells were treated with
drugs such as 5 mM NBQX, 1 mM LY341495, 2 mM PI828.
PI282 is a more potent form of LY294002 [43]. 5 mM
Wortmannin, 25 mM Iressa alone was used or in combination as
specified in each experiment for 72 hours. All drugs were
purchased from R&D systems, Minneapolis, MN.
Proliferation Assay
Post-drug treatment, the cells were fixed in 4% paraformalde-
hyde for 10 min and permeabilized in 0.2% Triton X-100 for
5 min. The cells were washed 3 times with 1X Phosphate buffered
saline (PBS) and then blocked with 10% bovine serum albumin
made in 1X PBS. Immunocytochemistry was carried out using
primary antibodies such as anti-mouse b III tubulin and anti-
rabbit Ki-67 followed by Alexa 488-conjugated anti-rabbit
secondary antibody and Alexa 568-conjugated anti-mouse anti-
body. The samples were mounted in mounting media (Molecular
Probes) containing DAPI for nuclear staining. Images were
captured at 20X magnification using a Zeiss fluorescence
microscope. The images were used for counting DAPI positive
and Ki-67 positive cells. At least five images were used from each
sample and the experiments were repeated at least four times. The
average obtained from all experiments is presented as total cell
numbers.
TUNEL Assay
TUNEL assay was performed using the In situ cell death
detection kit from Roche as per manufacturer’s instructions.
Briefly, after cells were fixed with 4% paraformaldehyde and
permeabilized in 0.2% Triton X-100, the TUNEL assay was
carried by incubating the fixed cells with the TUNEL reagent
containing TMR red labeled nucleotides at 37uC for 1 hour. The
samples were washed in 1X PBS and mounted in mounting media
containing DAPI. Fluorescent images were captured using a Zeiss
fluorescence microscope at 20X magnification. The total number
of DAPI positive cells and total number of TUNEL positive cells
were counted from at least five images from each sample. Each
experiment was repeated four times.
Glioma Growth Inhibition with Drug Combination
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Scratch Assay
Scratch assay was carried out as described by Goldberg and
Kloog [44]. Briefly, 1 million cells/well were seeded on poly-
lysine coated 6-well dishes. After 24 hours media was replaced
with glutamate free low serum media (0.5% FBS) containing
drugs. After 24 hours, three scratches were made and the media
was replaced with fresh media containing drugs. Images were
captured at 10X with a phase contrast inverted microscope at 0,
6, 18 and 24 hours. Each sample had three scratches and the
experiment was repeated three times. Gap width was calculated
by taking 50 measurements from each scratch to obtain the
average width. Each measurement was taken from the left edge
of the scratch to the right edge of the scratch going from top of
the image to the bottom of the image using Image J. Total 150
measurements were obtained from one sample in each
experiment to obtain the average width of the sample. Distance
travelled by the cells into the gap was calculated as arbitrary
units using the average width distance difference in samples at
0, 6, 18 and 24 hours.
Data Analysis
Statistical analysis was carried out using Microsoft Excel 2010.
One-way ANOVA was performed to test differences between
control and different drug-treated groups. Significance was
established at p-values ,0.05. To test differences within groups,
Tukey’s post-hoc analysis was carried out using Prism software,
GraphPad Software, Inc., La Jolla, CA. Significance was
established at p-values ,0.05.
Results
Dosage Curve of Glutamate on U87 Cell Growth
We aimed to study inhibition of glutamate-stimulated growth of
U87 cells. To demonstrate the effect of dose concentration of
exogenous glutamate on U87 cells in culture we used a
proliferation assay as described in Materials and Methods. At
5 mM glutamate concentration, the growth represented by DAPI
staining (blue bars) was similar to untreated control and cells
showed similar morphological features when compared with the
control sample. In contrast, at higher concentrations (25 mM,
50 mM or 75 mM glutamate), there was a significant reduction in
Figure 1. Glutamate activates several pathways to stimulate growth in glioblastoma cells. Glutamate activates Ca2+-permeable AMPA
receptors, EGFR receptor and group II metabotropic receptors. AMPA receptor, EGFR, and mGluR are stimulated by glutamate to activate overlapping
pathways for cell growth.
doi:10.1371/journal.pone.0064588.g001
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the total number of cells stained by DAPI (blue bars, Figure 2 A).
The cells that survived high glutamate exposure at 50 mM and
75 mM of glutamate showed large and flattened morphology by b
III tubulin staining (shown in red in Figure 2B). U87 cells show
heterogeneity in culture, where some cells grow in spheres with
rounder morphology while some grow as large flattened cells.
Interestingly, cells at both low and high glutamate concentration
showed Ki-67 staining (represented by green bars, Figure 2A). Ki-
67 staining labels the proliferating cells and high glutamate
concentrations seem to select a certain population of cells as shown
in Figure 2B. Notably, with 5 mM, the cells are smaller and
rounder whereas, with 75 mM, the cells are flatter and larger.
These morphological differences between samples treated with
5 mM and 75 mM are evident by b III tubulin staining in
Figure 2B. Interestingly, cells selected by high glutamate
concentration are also positive for proliferation marker, Ki-67.
There were no significant differences in the DAPI or Ki-65
staining between control and samples treated with 5 mM
glutamate. Based on these data, we infer that U87 cells maybe
secreting enough glutamate for their growth in the media, and
hence are not responding to exogenously added glutamate.
Riluzole Blocks Glutamate-dependent Growth of U87
Cells
Exogenous glutamate addition to U87 cultures did not result in
increased cell proliferation, therefore, we wanted to test if U87
cells were secreting sufficient glutamate to stimulate their growth.
We used Riluzole, a drug that blocks the secretion of glutamate
and enhances the uptake of glutamate from the extracellular space
thereby, reducing the effective concentration of glutamate in the
media [45]. To assess proliferation, DAPI stained cells were used
to score total cells and proliferating cells by counting Ki-67
positive cells. The results in Figure 3A show DAPI positive cells as
blue bars and Ki-67 positive cells as green bars. Figure 3B shows
percentage of proliferating cells based on total number of Ki-67
positive cells out of total number of DAPI positive cells. Compared
to the control sample Riluzole treated samples showed decreased
number of both DAPI positive and Ki-67 positive cells as the
concentration of Riluzole increased from 1 mM to 100 mM.
Figure 3B shows that in control sample 60% of the DAPI positive
cells were positive for Ki-67 marker. In contrast, at 1 mM Riluzole
only 30% of the DAPI positive cells were Ki-67 positive. The
percentage of Ki-67 positive cells decreased in a dose-dependent
manner up to a dose of 50 mM and remained same at 100 mM
Riluzole (Figure 3B). Thus, the percentage of proliferating cells
declined with increase in Riluzole concentration and Riluzole
treated samples were significantly different when compared to
untreated control sample with a p value of less than 0.05. Our
results demonstrate that Riluzole inhibits proliferation of U87 cells
in a dose-dependent manner, suggesting that the absence of
glutamate from media prevents glutamate-dependent prolifera-
tion. These results suggest that there is enough glutamate secreted
in the media for growth of U87 cells and Riluzole blocks the
release of glutamate in the media.
Iressa in Combination with LY341495 or PI828 is Effective
in Inhibiting Proliferation
It is well established that U87 cells proliferate in a glutamate-
dependent manner and drugs such as NBQX, an AMPA receptor
blocker or LY341495, an inhibitor of metabotropic glutamate
receptor have been shown to inhibit proliferation of glioma cells
[9,13]. We investigated the efficacy of combinations of different
Figure 2. Glutamate Dosage Curve on U87 cells. Serum starved U87 cells were treated with 5 mM to 75 mM concentrations of glutamate in the
media for 72 hours and the cells were fixed and stained with anti-rabbit Ki-67 antibody and anti-mouse b III tubulin antibody along with DAPI stain
for nuclei. ALEXA 488-conjugated anti-rabbit antibody and Alexa 568-conjugated anti-mouse antibodies were used as secondary antibodies. Images
were captured at 40X using a Zeiss fluorescence microscope. A. Total number of cells counted and average of 4 independent experiments based on
DAPI staining, blue bars and Ki-67 positive cells are shown as green bars. No significant (Not Significant, NS) differences were found between the
control and the sample treated with 5 mM glutamate for both DAPI and Ki-65 staining. B. Representative images of DMSO treated control or samples
treated with 5 mM and 75 mM glutamate.
doi:10.1371/journal.pone.0064588.g002
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classes of drugs in inhibiting the proliferation of U87 cells. The
samples were treated with DMSO, NBQX, LY341495,
NBQX+LY341495, Wortmannin, PI828 or Wortmannin plus
PI828. The total number of cells was scored by DAPI staining and
proliferating cells were scored by Ki-67 staining. Compared to the
control sample, all treatments showed decreases in total number of
cells but the differences were not significant. Significant differences
were observed between control and all drug treated samples for
Ki-67. As shown in Figure 4A, a combination of NBQX and
LY341495 was no more effective than NBQX or LY341495 alone
in inhibiting proliferation as indicated by green bars. A
combination of two kinase inhibitors, PI828 and Wortmannin,
was more efficaciously than PI828 or Wortmannin alone in
reducing the total number of cells (blue bars). However, no change
was observed in the percentage of proliferating cells when
compared to PI828 alone (indicated as green bars, Figure 4A).
We then tested NBQX, LY341495, PI828, or Wortmannin in
combination with Iressa, an inhibitor of epidermal growth factor
receptor (EGFR). Treatment of cells with Iressa alone resulted in
decreased proliferation compared to the untreated control as
shown in Figure 4B. Furthermore, Iressa in combination with
NBQX, LY341495, PI828, or Wortmannin decreased the total
number of cells when compared to the individual drugs alone as
shown as blue bars in Figure 4B. Significantly, Iressa, decreased
the total number of cells in combination with LY341495, NBQX,
or with PI828. Moreover, Iressa also decreased the number of
proliferating cells when used in combination with PI828 or
LY341495 shown as green bars in Figure 4B. The results in these
experiments demonstrate that combination of Iressa with
LY341495 or PI828 is more effective in inhibiting the proliferation
of cells compared to the individual drugs alone. The differences in
the proliferation of cells in samples treated with individual drugs
(Iressa, LY341495, PI828) versus Iressa plus LY341495 or Iressa
plus PI828 was significant with a p value of less than 0.05.
Iressa in Combination with LY341495 Induces Maximal
Apoptosis in U87 Cells
Some drugs such as NBQX have been shown to inhibit growth
by inducing apoptosis in CGNH-89 cells [13]. We tested the effect
of combination of drugs in inducing apoptosis in U87 cells using a
TUNEL assay. Total number of cells were scored by DAPI
staining and apoptotic cells were scored by TUNEL staining.
Representative images from the experiments are shown in
Figure 5C and 5F. Percentage of apoptotic cells was calculated
using total DAPI positive cells and total TUNEL positive cells
from four independent experiments. Treatment with NBQX alone
or LY341495 alone induced increased apoptosis compared to
untreated control Figure 5A. A combination of NBQX and
LY341495 induced an increased percentage of apoptosis when
compared with either NBQX or LY341495 alone (Figure 5B).
Treatment with PI828 or Wortmannin resulted in increased
apoptosis compared to untreated control, however, the samples
treated with both PI828 and Wortmannin together did not further
increase the percent of apoptosis compared to that of PI828 or
Wortmannin alone as shown in Figure 5A and 5B. Samples were
also treated either with Iressa alone or Iressa in combination with
LY341495, NBQX, PI828 or Wortmannin (Figure 5D–F).
Treatment with Iressa resulted in increased apoptosis compared
to control. Interestingly, treatment of samples with Iressa in
combination with PI828 or Wortmannin did not increase
apoptosis in cells but was less effective when compared to
treatment with PI828 or Wortmannin as shown in Figure 5E
and 5B. However, treatment of samples with Iressa and NBQX or
Iressa and LY341495 increased apoptosis compared to Iressa
alone, NBQX alone or LY341495 alone (Figure 5E and 5B).
Maximum percentage of apoptosis was observed in the Iressa and
LY341495 treated sample. Significant differences were found
between Iressa plus LY341495 and Iressa plus NBQX or Iressa
plus PI828 or Iressa plus Wortmannin. Curiously, the differences
between the control sample and sample treated with Iressa plus
LY341495 were not significant for TUNEL positive cells. This is
due to a huge loss of cells by apoptosis in Iressa plus LY341495
treated sample. On the contrary, percentage of apoptotic cells
between the control and Iressa plus LY341495 treated samples
were highly significant. Control samples showed fewer number of
TUNEL positive cells just like in Iressa plus LY341495. However,
the number of DAPI positive cells in control far exceeds the
number of DAPI positive cells in Iressa plus LY341495. These
Figure 3. Riluzole inhibits cell proliferation in U87 cells. A. Proliferation was measured in the presence of Riluzole at various concentrations as
indicated. The blue bars represent total number of DAPI positive cells and the green bars represent total number of Ki-67 positive cells. B. The
percentage of Ki-67 positive cells of the total DAPI positive cells in untreated control or at various concentrations of Riluzole. The inhibition by
Riluzole occurs at all doses and is significantly different when compared to the control sample, p value 0.05 by ANOVA.
doi:10.1371/journal.pone.0064588.g003
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results suggest that the most effective drug combination treatment
to achieve maximum apoptosis is with Iressa plus LY341495.
Iressa in Combination with LY341495 Blocks Migration of
U87 Cells
Glioblastoma cells have been shown to migrate in response to
glutamate release and blocking XC-mediated glutamate release
disrupted glioma invasion [11]. Migration of U87 cells under
untreated conditions and drug treated conditions were tested using
a scratch assay. We performed the scratch assay as described in the
Materials and Methods section. Figure 6A shows representative
images from each sample that was used to collect and analyze
data. Figure 6B shows the average gap width in each sample at 0,
6, 18 and 24 hours. The control sample showed an average width
of 5 and less than 4 arbitrary units at 18 and 24 hours respectively.
In samples treated with Iressa alone, the average gap width was 7
at 18 and 24 hours. Treatment with LY341495 resulted in the gap
width of 7 and 7.5 at 18 and 24-hour time points. Samples treated
with both Iressa and LY341495 showed an average width of
Figure 4. Iressa plus LY341495 inhibit proliferation of U87 cells. A. Proliferation assay was performed either in vehicle treated or samples
treated with NBQX, 5 mM, LY341495 1 mM, NBQX+LY341495, Wortmannin 5 mM, PI828 2 mM or Wortamannin+PI828. Total number of DAPI positive
cells is represented as blue bars and Ki-67 positive cells are represented as green bars. B. Proliferation assay was carried using Iressa 25 mM or
combination of Iressa with NBQX or LY341495 or PI828 or Wortmannin as shown. Blue bars represent DAPI positive cells and green bars represent Ki-
67 positive cells. DAPI staining in both 3A and 3B, control vs. PI was significantly different (p value,0.05, **) while others (N, L, W vs. control were not
significant). DAPI staining in 3B control vs. N+I, control vs. L+I, control vs. W+I and control vs. P+I were significantly different (p value,0.05). For Ki-65
staining in Figure 3A, differences in control vs. drug treated samples were significant with a p value of ,0.05. In Figure 3B all drug treated samples
against control were significantly different. More importantly L+I or PI+I are significantly different from N+I or W+I with a p value of ,0.05 with
Tukey’s Multiple Comparison Test.
doi:10.1371/journal.pone.0064588.g004
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around 10 units. The distance migrated by cells was significantly
reduced in samples treated with Iressa and LY341495 compared
to samples treated with Iressa alone or LY341495 alone or control
sample (Figure 6C). The inhibition of cell migration in Iressa plus
LY341495 treated sample may be due to both inhibition of
proliferation and onset of apoptosis. There were more rounded
dead cells in the Iressa plus LY341495 samples when compared to
control or Iressa alone, or LY341495 alone (data not shown).
These results demonstrated that a combination of Iressa and
LY341495 works synergistically in blocking the migration of U87
cells.
Discussion
We examined the effectiveness of drugs targeting various
pathways involved in glutamate-dependent growth, such as,
AMPA receptor-mediated, mGluR-activated, EGFR-dependent
pathways. We tested the effectiveness of combination of drugs
Figure 5. Iressa plus LY341495 induces apoptosis in U87 cells. Apoptosis was measured using TUNEL assay in samples either treated with
vehicle for control or treated with LY341495, NBQX, NBQX+LY341493, PI828, Wortmannin or PI828+Wortmannin. A. Blue bars represent DAPI positive
cells and red bars represent TUNEL positive cells. B. Percentage of TUNEL positive cells in each sample. C. Representative images of the TUNEL assay.
Apoptosis was measured using TUNEL assay in samples either treated with vehicle for control or treated with Iressa or Iressa with LY341495 or NBQX
or PI828 or Wortmannin. D. Blue bars represent DAPI positive cells and red bars represent TUNEL positive cells. E. Percentage of TUNEL positive cells
in each sample. F. Representative images of the TUNEL assay. For 4A DAPI, no significant differences were found between samples except in control
vs. PI and control vs. W+PI (p value ,0.05). For TUNEL assay, no significant differences were found between any two samples using Tukey’s Multiple
Comparison Test. In Figure 4D with DAPI staining, significant differences exist between control vs. I, control vs. I+L, control vs. I+N, control vs. I+PI,
and control vs. I+W with a p value of,0.05. Significant differences were seen between I vs. I+L, I+L vs. I+N, I+L vs. I+PI and I+L vs. I+W (p value,0.05).
For TUNEL positive cells significant differences were found between control vs. I, control vs. I+N, control vs. I+PI and control vs. I+W. No difference was
obtained when control was compared to I+L. Significant differences were obtained between I+L vs. I+N, I+L vs. I+PI, and I+L vs. I+W (p value ,0.05).
Figure 4E. The percentage apoptosis is highly significant between the control and I+L samples with a p value ,0.0005 (***).
doi:10.1371/journal.pone.0064588.g005
Figure 6. Iressa plus LY341495 inhibit U87 cell migration. Scratch assay was used to measure migration of U87 cells. Cells were either treated
with vehicle for control or treated with 25 mM Iressa, 1 mM LY341495, or Iressa+LY341494, then scratched and images of the gap created were
captured at 0 h, 6 h, 18 h and 24 h using phase contrast inverted scope. A. Representative images of the scratch in samples at 0 h, 6 h and 24 h. B.
The gap distance was measured from 3 scratches in each sample at 0 h, 6 h, 18 h and 24 h using NIH image J. C. The distance travelled by the cells
was calculated based on decrease in gap width distance at 0 h, 6 h 18 h and 24 h. Samples treated with Iressa plus LY341495 showed significantly
more inhibition of cell migration when compared to samples treated with Iressa alone or LY341495 alone p value ,0.05.
doi:10.1371/journal.pone.0064588.g006
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targeting above pathways. Drugs targeting EGFR and mGluR
have been shown to block proliferation of U87 cells [9,30]. Our
results suggest that a combination of LY341495, mGluR blocker,
and Iressa, EGFR blocker is effective in preventing proliferation of
U87 cells and in inducing apoptosis in about 90% of the cells.
LY341495 plus Iressa is also very effective in inhibiting migration
of U87 cells. The synergistic effect of Iressa and LY341495 may be
due to the inhibition of converging and overlapping pathways such
as Akt-1 and MAP kinase pathways. These two pathways have
been shown to be utilized both by EGFR and mGluR upon
activation by glutamate [9,39,41,42].
In the present study, we show that higher glutamate exposure to
U87 cells results in selection of flattened and enlarged cells. These
enlarged and flattened cells were positive for the proliferation
marker Ki-67. This result may suggest that high glutamate
selection may be based on the differences in glutamate tolerance
by these cells. It is possible that the glutamate receptors including
NMDA and AMPA receptor expression in these cells may be
different compared to those of glutamate susceptible cells and
needs to be further investigated. We show that Riluzole treatment
results in the inhibition of proliferation of U87 cells. Riluzole has
been shown to block proliferation, invasion and migration of
melanoma cells [46]. It is interesting to note that Riluzole in
prostrate cancer lines has been shown to block DNA synthesis and
induce apoptosis via the induction of ER stress [46]. Furthermore,
in breast cancer Riluzole has shown promising results by inhibiting
proliferation [47]. However, the mechanism by which the lack of,
or low, glutamate inhibits proliferation in U87 cells may be due to
lack of stimulation of AMPA receptor, mGluR or EGFR
pathways. Further investigation is needed to study the mechanism
by which Riluzole is inhibiting proliferation of U87 cells.
Ca2+-permeable AMPA receptors are expressed in U87 cells,
which lack subunit GluR2 [13]. GluR2 subunit, which is normally
edited in healthy brain when incorporated into AMPA receptor
forms Ca2+-impermeable channels. Overexpression of GluR2 in
U87 cells has been shown to inhibit proliferation by inactivation
ERK1/2-Src pathway [48]. GluR2 is unedited in some glioblas-
tomas, which results in Ca2+-permeable AMPA receptors [49].
AMPA receptor channels either containing unedited GluR2 or
lacking GluR2 form Ca2+-permeable channels and such channels
are involved in invasive and aggressive growth behavior in
glioblastoma [13,49]. The AMPA receptor blocker NBQX is well
documented to block proliferation and migration of glioblastoma
cells [13,18]. However, we did not detect significant inhibition by
NBQX even at higher concentrations (50 mM or 100 mM data not
shown) or in combination with LY341495. Higher concentration
of the drug resulted in precipitation of the drug in the cultures. It
has been reported earlier in animals to cause nephrotoxicity due to
precipitation of the drug in the kidneys [50]. The lack of adequate
inhibition effect by NBQX may be due to a lower concentration of
the drug (5 mM) or maybe due to partial or complete non-
functionality of AMPA receptors in U87 cells where the subunits
such as GluR1, GluR2 and GluR3 although expressed may not
assemble into functional AMPA receptor channels [19]. Ca2+
influx through the AMPA receptors activates PI3K independent
phosphorylation of Akt at Serine 473, which promotes prolifer-
ation and migration of CGNH89 cells [17]. Data suggests that
inhibition by NBQX is not the most effective way to block cell
proliferation of U87 cells. Rather, a combination of LY341495
and Iressa that target both mGluR and the EGFR is most effective
in blocking proliferation of U87 cells.
PI828 and Wortmannin, both inhibitors of PI3K, showed
differences in their ability to block proliferation of U87 cells. PI828
was more effective than Wortmannin in blocking proliferation.
This difference may be explained based on studies that have
demonstrated reduced specificity of LY294002 as a PI3K inhibitor
compared to Wortmannin [51,52,53]. Our data shows that PI828
is more effective in combination with Iressa when compared to
Iressa plus Wortmannin in inhibiting proliferation.
Combination of LY341495 plus Iressa resulted in decreased
proliferation and cell survival based on the DAPI numbers
(Figure 4B). Combination of LY341495 plus Iressa also induced
maximal apoptosis in almost 90% of the cells when compared to a
40% by Iressa and 10% by LY341493 individually (see Figure 5E
and 5B). We believe that this combination acts synergistically,
blocking proliferation and inducing apoptosis, and may also be
effective in vivo due to high penetration of LY341495 into brain
and adequate levels of Iressa in the brain [9,54].
A large number of glioblastomas show EGFR amplification
[31,32] and the combination of Iressa and LY341495 may be
suited to block the proliferation of many tumors with EGFR
misregulation. AMPA receptor activation and EGFR activation
target the same signaling molecules, such as Akt. However, the
kinase involved in the activation of Akt, at least at the S473 site
may be different depending on path of activation [17]. Our data
suggests that a more positive feedback loop exist between mGluR
and EGFR activation in U87 cells, because a combination of
inhibition of mGluR and EGFR is more effective than combina-
tion of inhibition AMPA receptor and EGFR inhibition. The
synergism exhibited by Iressa and LY341495 may stem from the
fact that they inhibit activation of Akt-1 and ERK1/2 activation
via the inhibition of EGFR and mGluR activation [9,39,41].
Depending on the pathways activated in different gliomas, the
combination of inhibitors that block growth proliferation and
induce apoptosis may be different. Conclusively, we demonstrated
that a combinatorial drug treatment with Iressa and LY341495
acts synergistically in inhibiting glutamate-dependent proliferation,
inducing apoptosis and inhibiting migration of U87 cells. We
believe that the synergism is due to convergence of two pathways
namely the Akt pathway and the MAP kinase pathway and both
pathways are activated by EGFR and mGluR upon glutamate-
dependent activation.
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